eIF1AY inhibitors represent a class of compounds that specifically target and inhibit the activity of the eukaryotic translation initiation factor 1A (eIF1A), which is essential in the initiation phase of protein synthesis. eIF1A plays a crucial role in stabilizing the binding of the initiator tRNA to the small ribosomal subunit and promoting the proper scanning of the messenger RNA (mRNA) for the start codon. By inhibiting eIF1A, these compounds disrupt the normal initiation process, leading to a decrease in overall protein synthesis. This inhibition can have significant effects on cellular processes, as protein synthesis is fundamental to cell growth, division, and response to environmental stimuli.
The mechanism of action of eIF1AY inhibitors involves binding to specific sites on the eIF1A protein, thereby preventing its interaction with the ribosomal subunits and other initiation factors. This binding can induce conformational changes in eIF1A, rendering it incapable of performing its function in the initiation complex. The development and study of eIF1AY inhibitors have provided valuable insights into the molecular dynamics of translation initiation and the regulatory mechanisms controlling protein synthesis. These compounds have also been used as tools in research to dissect the roles of eIF1A in various cellular pathways and to understand the broader implications of translational control in cellular physiology. The study of eIF1AY inhibitors continues to be a dynamic field, contributing to our understanding of the intricate processes that govern gene expression at the translational level.
VER TAMBIÉN ....
Items 11 to 16 of 16 total
Mostrar:
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Los daños en el ADN provocados por la doxorrubicina pueden hacer que la célula dé prioridad a la reparación del ADN sobre las funciones habituales, suprimiendo potencialmente la maquinaria del ARNi y disminuyendo los niveles de eIF2C2. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
La inhibición de la topoisomerasa I por parte de la camptotecina puede causar daños en el ADN, lo que podría conducir a una menor concentración en los procesos de ARNi y la consiguiente disminución de la expresión de eIF2C2. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Al inhibir la Hsp90, la geldanamicina puede desestabilizar las proteínas asociadas al ARNi, lo que podría incluir una disminución de la estabilidad o la síntesis de eIF2C2. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Un compuesto natural aislado de la planta Aglaia foveolata, conocida por su potente inhibición de EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Otro compuesto natural que se encuentra en varias plantas, como las del género Aglaia, con una fuerte actividad inhibidora de EIF4AI. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
Un inhibidor sintético de EIF4AI diseñado para interrumpir el complejo eIF4F, inhibiendo así la traducción cap-dependiente. | ||||||